Founded by Harold Meckler and Karl Popp in 2014, Pharmapotheca A develops pharmaceutical chemistry technologies and supplies patent-protected compounds for chemical and pharmaceutical research. The Delmar company focuses on amphetamine-related synthesis, controlled-release and abuse-deterrent dosage-form technologies, with its intellectual property exclusively licensed in part from Chemapotheca. In 2020, synthetic organic chemist Thomas E. D’Ambra joined as CEO to guide the company’s expansion.